Status:
TEMPORARILY_NOT_AVAILABLE
Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors
Lead Sponsor:
Providence Health & Services
Conditions:
KRAS G12V Mutant Advanced Epithelial Cancers
Eligibility:
All Genders
18+ years
Brief Summary
This intermediate-size IND will treat participants with incurable, advanced or metastatic cancer, harboring KRAS G12V mutation and appropriate HLA class II match (HLA-DRB1\*07:01).
Detailed Description
This study will treat two identified patients with metastatic pancreatic adenocarcinoma and metastatic pancreatic cancer who have both been treated with standard of care therapies and found to have di...
Eligibility Criteria
Inclusion
- Patients with incurable, advanced or metastatic cancer, harboring KRAS G12V mutation, and appropriate HLA class II match (HLA-DRB1\*07:01)
Exclusion
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05389514
Last Update
November 20 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.